L-carnitine supplementation in dialysis: treatment in quest of disease
- PMID: 23173999
- DOI: 10.1111/sdi.12041
L-carnitine supplementation in dialysis: treatment in quest of disease
Abstract
L-Carnitine (LC) administration has been recommended for specific indications in dialysis patients, including epoetin-resistant anemia, intradialytic hypotension, cardiomyopathy, fatigue, muscle weakness, and exercise performance; it may ameliorate insulin resistance, inflammation, and protein wasting. Use of LC for anemia and intradialytic hypotension has been approved for reimbursement by the Centers for Medicare and Medicaid Services. Yet, the data to support these recommendations are inadequate and have not been bolstered over several decades. LC administration continues to appeal to nephrologists because its use in dialysis patients has an attractive rationale, it addresses problems that persist despite dialysis, it is safe, and the existing literature does not refute its use. Nevertheless, definitive trials to justify LC administration have not been conducted and are increasingly unlikely to be funded. In an era of shrinking resources and bundling of dialysis services, the use of LC in dialysis patients will, appropriately, diminish.
© 2012 Wiley Periodicals, Inc.
Similar articles
-
L-carnitine supplementation in dialysis patients: does the evidence justify its use?Semin Dial. 2005 Jan-Feb;18(1):1-2. doi: 10.1111/j.1525-139X.2005.18104.x. Semin Dial. 2005. PMID: 15663752
-
Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients.Blood Purif. 2006;24(1):128-39. doi: 10.1159/000089449. Blood Purif. 2006. PMID: 16361853 Review.
-
Dialysis-related carnitine disorder.Semin Dial. 2006 Jul-Aug;19(4):323-8. doi: 10.1111/j.1525-139X.2006.00180.x. Semin Dial. 2006. PMID: 16893411 Review.
-
Debate forum: carnitine supplements have not been demonstrated as effective in patients on long-term dialysis therapy.Blood Purif. 2006;24(1):140-2. doi: 10.1159/000089450. Blood Purif. 2006. PMID: 16361854 Review.
-
L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?Nephrol News Issues. 2003 Apr;17(5):28-30, 32-4, 36 passim. Nephrol News Issues. 2003. PMID: 12715624 Review.
Cited by
-
Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.Clin J Am Soc Nephrol. 2018 Mar 7;13(3):436-444. doi: 10.2215/CJN.08790817. Epub 2018 Feb 14. Clin J Am Soc Nephrol. 2018. PMID: 29444900 Free PMC article.
-
Carnitine Inborn Errors of Metabolism.Molecules. 2019 Sep 6;24(18):3251. doi: 10.3390/molecules24183251. Molecules. 2019. PMID: 31500110 Free PMC article. Review.
-
Prevention of Intradialytic Hypotension in Hemodialysis Patients: Current Challenges and Future Prospects.Int J Nephrol Renovasc Dis. 2023 Aug 1;16:173-181. doi: 10.2147/IJNRD.S245621. eCollection 2023. Int J Nephrol Renovasc Dis. 2023. PMID: 37547077 Free PMC article. Review.
-
Differential effects of oral and intravenous l-carnitine on serum lipids: is the microbiota the answer?Clin Kidney J. 2014 Oct;7(5):437-41. doi: 10.1093/ckj/sfu099. Clin Kidney J. 2014. PMID: 25878774 Free PMC article. No abstract available.
-
Mitochondria: a new therapeutic target in chronic kidney disease.Nutr Metab (Lond). 2015 Nov 25;12:49. doi: 10.1186/s12986-015-0044-z. eCollection 2015. Nutr Metab (Lond). 2015. PMID: 26612997 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
